Aegerion Pharmaceuticals (AEGR) Getting Somewhat Favorable Press Coverage, Analysis Finds

News stories about Aegerion Pharmaceuticals (NASDAQ:AEGR) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Aegerion Pharmaceuticals earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 44.3337447910078 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

COPYRIGHT VIOLATION WARNING: This article was posted by [[site]] and is the property of of [[site]]. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at [[permalink]].

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.